Most recent update: Wednesday, December 11, 2019 - 10:54

Bariatric News - Cookies & privacy policy

You are here

metabolic disease

PGRMC2 protein may play key role in obesity and metabolic disease

Researchers at Scripps Research have revealed critical new understandings about obesity and metabolism, which could lead to new approaches for addressing obesity and potentially many other diseases. The signalling protein, progesterone receptor membrane component 2 (PGRMC2), had not been extensively studied in the past, and has been detected in the uterus, liver and several areas of the body.

Researchers investigate autophagy’s role in metabolic disease

Researchers at the University of Florida are investigating how autophagy - the body's way of cleaning out damaged cells, in order to regenerate newer, healthier cells - plays a role in metabolic diseases such as obesity and type 2 diabetes.

Higher BMI linked with increased risk of serious health problems

A new study has shed light on the link between higher body mass index (BMI) and serious health outcomes and death in over 2.8 million adults representative of the UK population. The new estimates, presented at this year's European Congress on Obesity (ECO) in Glasgow, UK, indicate that adults with severe obesity class III (BMI40-45) are 12 times as likely to develop type 2 diabetes and are at 22 times greater risk of sleep apnoea than their normal weight peers. Those individuals with obesity class I (BMI30-35) are at 70% higher risk of developing heart failure.

Drug targets enzyme linked to insulin resistance

Researchers at the Centenary Institute and UNSW Sydney, Australia, have created a drug which targets an enzyme linked to insulin resistance, a key contributor of metabolic diseases. The project is a collaboration between the Centenary Institute's Associate Professor Anthony Don, UNSW's Metabolic research group and its leader Associate Professor Nigel Turner, and UNSW Professor Jonathan Morris' synthetic chemistry group.

GTF2IRD1 molecule reduces obesity and diabetes in mice

UC San Francisco researchers have discovered a new biological pathway in fat cells that could explain why some people with obesity are at high risk for metabolic diseases. The new findings, demonstrated initially in mice and supported by data from human patients, could lead to new biomarkers to predict who is at risk and guide treatments to reduce the medical burden of obesity.

Omega-3 fatty acids found to stimulate brown adipose tissue

Omega-3 fatty acids are able to stimulate the activation of brown and beige adipose tissues, a discovery that would promote the development of new therapies for obesity and other metabolism diseases, according to a research study published under the supervision of Professor Francesc Villarroya, from the Department of Biochemistry and Molecular Biomedicine and the Biomedical Research Center Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN) of the Institute of Health Carlos III.

Studies show link between obesity and skeletal health

Two published studies have demonstrated the negative impact obesity and metabolic disease can have on skeletal health. The first study published in the Journal of Bone & Joint Surgery (JBJS) has found a link between obesity and a higher risk for surgery in orthopaedic trauma patients. In addition, researchers found that patients with obesity had longer hospital stays and greater treatment costs. They were also more likely to be discharged to a care facility, rather than to home.

Clinical value of defining metabolic health is limited

Definitions of metabolic health that have been proposed to help explain differences in the risk of developing type 2 diabetes between people of different weight may be less helpful than was thought, according to a meta-analysis of data from over 140,000 individuals published in Diabetes Care (‘Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis‘).

A review of Ileal interposition surgery for T2DM

Ileal Interposition in combination with Sleeve Gastrectomy (IISG) and Diverted Sleeve Gastrectomy (IIDSG) is known to improve glycemic control and lead to a significant reduction in oral hypoglycemic agents (OHAs) and insulin therapy.

SG has similar outcomes to RYGB in Chinese patients

Sleeve gastrectomy has similar effects to RYGB in remission of T2DM and metabolic disorders for Chinese mildly obese (BMI28-35) T2DM patients, according to Chinese researchers from the First Affiliated Hospital of Jinan University, Guangzho, China.

Subscribe to RSS - metabolic disease